Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets

Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 meg, 25 meg, and 50 meg (US RLD: Cytomel Tablets).

Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 312 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.460.3 as compared to the previous close of Rs. 469.4. The total number of shares traded during the day was 138476 in over 2850 trades.

The stock hit an intraday high of Rs. 473.15 and intraday low of 455.35. The net turnover during the day was Rs. 64399911.

Source : Equity Bulls

Keywords